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Clinical PerspectiveWhat Is New?Approximately 50% of the patients undergoing transcatheter aortic valve replacement are in a state of low flow (LF; eg, stroke volume index ≤35 mL/m^2^).An LF aortic stenosis is associated with a higher all‐cause and cardiovascular mortality compared with normal‐flow aortic stenosis in patients undergoing transcatheter aortic valve replacement and is, in contrast to left ventricular ejection fraction and mean pressure gradient, an independent predictor of all‐cause and cardiovascular mortality.Patients with paradoxical LF--low‐gradient aortic stenosis have comparable outcomes to patients with classic LF--low‐gradient aortic stenosis.Despite differences in mortality, surviving patients showed similar improvements in functional capacity across all examined entities of aortic stenosis.What Are the Clinical Implications?Despite the higher long‐term mortality in patients with paradoxical LF--low‐gradient and classic LF--low‐gradient aortic stenosis, these patients have a high transcatheter aortic valve replacement procedural success and low procedural mortality.Marked improvement in functional capacity is also evident among survivors.Our findings suggest that these patients are, therefore, in need of early treatment because of advanced disease and do not represent a futile patient cohort.

Introduction {#jah33027-sec-0008}
============

Impaired left ventricular (LV) function is a frequent finding in patients with calcific aortic stenosis (AS).[1](#jah33027-bib-0001){ref-type="ref"} LV ejection fraction (LV‐EF) has affected survival after surgical aortic valve replacement[2](#jah33027-bib-0002){ref-type="ref"}, [3](#jah33027-bib-0003){ref-type="ref"}, [4](#jah33027-bib-0004){ref-type="ref"} and has consequently been incorporated in statistical models for assessment of operative risk.[5](#jah33027-bib-0005){ref-type="ref"} Conversely, in transcatheter aortic valve replacement (TAVR), which has been a safe and effective treatment for patients at intermediate[6](#jah33027-bib-0006){ref-type="ref"} and high surgical risk,[7](#jah33027-bib-0007){ref-type="ref"} the relationship is less clear.[8](#jah33027-bib-0008){ref-type="ref"}, [9](#jah33027-bib-0009){ref-type="ref"}, [10](#jah33027-bib-0010){ref-type="ref"}, [11](#jah33027-bib-0011){ref-type="ref"}, [12](#jah33027-bib-0012){ref-type="ref"}

A more comprehensive indicator of LV function is stroke volume index (SVI) because of the fact that in the setting of marked LV hypertrophy and diastolic dysfunction, LV‐EF does not reflect the complex capacity of the LV.[13](#jah33027-bib-0013){ref-type="ref"} Reduced stroke volume (eg, low flow \[LF\]) leads to a reduced pressure gradient despite severe AS creating the entity of "LF--low‐gradient (LG) AS."[14](#jah33027-bib-0014){ref-type="ref"} This can be further subdivided into a "classic" type with reduced LV‐EF and a "paradoxical" type with preserved LV‐EF, with the latter characterized by impaired longitudinal deformation, diastolic dysfunction, and a small LV volume causing the impairment in LV function.[15](#jah33027-bib-0015){ref-type="ref"} LF states are associated with either poor prognosis, if treated medically,[16](#jah33027-bib-0016){ref-type="ref"} or with increased operative mortality, if treated by surgical aortic valve replacement[16](#jah33027-bib-0016){ref-type="ref"}, [17](#jah33027-bib-0017){ref-type="ref"}, [18](#jah33027-bib-0018){ref-type="ref"} or TAVR.[19](#jah33027-bib-0019){ref-type="ref"} Data in TAVR cohorts are characterized by different definitions of AS entities and missing information on SVI, leading to an inconclusive assessment on the impact of LV‐EF, mean pressure gradient (MPG), and SVI on outcome.[1](#jah33027-bib-0001){ref-type="ref"}, [9](#jah33027-bib-0009){ref-type="ref"}, [10](#jah33027-bib-0010){ref-type="ref"}, [19](#jah33027-bib-0019){ref-type="ref"}, [20](#jah33027-bib-0020){ref-type="ref"}, [21](#jah33027-bib-0021){ref-type="ref"}, [22](#jah33027-bib-0022){ref-type="ref"}, [23](#jah33027-bib-0023){ref-type="ref"} Beyond survival, it is also recognized that some patients fail to experience a benefit in functional capacity or morbidity after TAVR.[24](#jah33027-bib-0024){ref-type="ref"} Therefore, the need for identifying the subgroups of patients in whom TAVR is likely to be futile remains a priority.

In this study, we examined the impact of SVI, MPG, and LV‐EF on mortality and functional capacity after TAVR in a large, single‐center, all‐comers cohort.

Methods {#jah33027-sec-0009}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Patient Cohort {#jah33027-sec-0010}
--------------

From February 24, 2006 to September 17, 2014, a total of 1821 consecutive patients were treated with a transfemoral TAVR in our tertiary center after discussion of the best treatment option in a multidisciplinary heart team.[25](#jah33027-bib-0025){ref-type="ref"} For this analysis, patients were excluded if they were treated because of aortic valve bioprosthesis failure (n=62) or pure aortic regurgitation (n=3) or if they had incomplete baseline echocardiographic data (n=156). Baseline characteristics, procedural data, and outcome data were prospectively collected. Follow‐up was performed after 30 days, 12 months, and up to 3 years. Presence of lung disease was defined according to the EuroScore definition.[26](#jah33027-bib-0026){ref-type="ref"} Immunosuppressant medication, diabetes mellitus, coronary heart disease, and peripheral artery disease were defined according to the Society of Thoracic Surgeons Predicted Risk of Mortality score.[27](#jah33027-bib-0027){ref-type="ref"} Society of Thoracic Surgeons Predicted Risk of Mortality score and logistic EuroScore I were calculated. The registry was approved by the Ethics Committee of the University of Leipzig (registration no. 167‐10‐12072010), and all patients gave written informed consent.

Echocardiography {#jah33027-sec-0011}
----------------

LV‐EF and LV outflow tract diameter were acquired by echocardiography. Doppler velocity measurements of LV outflow tract flow and transvalvular flow were measured, and stroke volume and aortic valve area were calculated using the continuity equation. Peak and mean transaortic gradients were computed using the Bernoulli equation. SVI and aortic valve area index were calculated using the body surface area, as determined by the DuBois formula. Patients were primarily separated into normal flow (NF; SVI \>35 mL/m^2^) and LF (SVI ≤35 mL/m^2^). In a second analysis, patients were further stratified into 4 groups according to a current guideline definition[28](#jah33027-bib-0028){ref-type="ref"}: "NF--high gradient" (NF‐HG; SVI \>35 mL/m^2^, MPG \>40 mm Hg), "NF‐LG" (SVI \>35 mL/m^2^, MPG ≤40 mm Hg), "LF‐LG" (SVI ≤35 mL/m^2^, MPG ≤40 mm Hg), and "LF‐HG" (SVI ≤35 mL/m^2^, MPG \>40 mm Hg). The LF‐LG group was additionally separated into classic LF‐LG (cLF‐LG; LV‐EF \<50%) and paradoxical LF‐LG (pLF‐LG; LV‐EF ≥50%).

End Points {#jah33027-sec-0012}
----------

The primary end point was 3‐year all‐cause mortality. Thirty‐day all‐cause mortality served as a secondary end point. Occurrence of periprocedural myocardial infarction, stroke, renal failure, bleeding, and access site complications was evaluated according to the Valve Academic Research Consortium‐2 defintion.[29](#jah33027-bib-0029){ref-type="ref"} Causes of death were categorized into cardiovascular and noncardiovascular causes, also according to Valve Academic Research Consortium‐2. Functional capacity was assessed by the New York Heart Association (NYHA) class and was evaluated at baseline and after 6 to 12 months.

Statistical Analysis {#jah33027-sec-0013}
--------------------

The statistical analysis was performed using SPSS Statistics, version 22.0 (IBM Corporation, Armonk, NY). Categorical variables are expressed as numbers and percentage and were compared with the use of χ^2^ test. Continuous variables are expressed as median with the corresponding 25th and 75th quartile and were compared using the Kruskal‐Wallis test because of nonnormal distribution assessed with the Shapiro‐Wilk test. To prove the cutoff value of 35 mL/m^2^ for SVI, the optimal cutoff in our cohort was determined by receiver‐operating characteristic curve analysis and the Youden index. The 30‐day and 3‐year mortality rates were analyzed according to the method of Kaplan‐Meier, and group comparisons were made applying the log‐rank test. Independent predictors of mortality were determined with Cox proportional hazards regression models for all‐cause and cardiovascular mortality at 3 years. Clinically relevant variables with a *P*\<0.1 in univariate analysis were included in the model. Age was forced into the model for all‐cause mortality. Two different models were created: one only including baseline variables and one including baseline and periprocedural variables. LogEuroScore, Society of Thoracic Surgeons Predicted Risk of Mortality score, and body mass index were naturally log transformed because they were nonnormally distributed. NYHA class at baseline and follow‐up was analyzed as a paired test. *P*\<0.05 was considered significant.

Results {#jah33027-sec-0014}
=======

Determination of the Optimal Cutoff for SVI {#jah33027-sec-0015}
-------------------------------------------

The optimal cutoff value for SVI, as determined by Youden index, was 34.4 mL/m^2^ in our cohort (Figure [S1](#jah33027-sup-0001){ref-type="supplementary-material"}). To keep it comparable to other studies, \<35 mL/m^2^ was defined as cutoff for the definition of LF.

Baseline Characteristics {#jah33027-sec-0016}
------------------------

Of 1600 patients, 789 (49.3%) were diagnosed as having LF and 811 (50.7%) had NF. After further subdivision, 522 patients (32.6%) had NF‐HG, 289 patients (18.1%) had NF‐LG, 405 patients (25.3%) had LF‐LG, and 384 patients (24.0%) had LF‐HG. Of the 405 patients with LF‐LG, 225 (14.1% of the total population) had cLF‐LG and 180 (11.3%) had pLF‐LG. Baseline characteristics and echo parameters are depicted in Table [1](#jah33027-tbl-0001){ref-type="table"}, showing substantial differences between groups. Specifically, the proportion of younger and male patients was significantly higher in cLF‐LG. Moreover, patients with cLF‐LG had a higher logistic EuroScore I, had more cardiovascular comorbidities, and more often had chronic kidney disease. In contrast, patients with pLF‐LG were more often women and had the highest prevalence of preexisting atrial fibrillation. All patients were highly symptomatic, with ∼70% to 80% having dyspnea, according to NYHA class III/IV. Levels of NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) were increased in all groups, with highest values found in cLF‐LG and LF‐HG and comparable levels in NF‐HG, NF‐LG, and pLF‐LG.

###### 

Baseline Characteristics

  Characteristics               NF‐HG (n=522)       NF‐LG (n=289)       LF‐HG (n=384)       cLF‐LG (n=225)      pLF‐LG (n=180)      *P* Value
  ----------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -----------
  Age, y                        81 (77--84)         81 (77--84)         81 (77--85)         79 (74--83)         81 (77--84)         \<0.001
  Male sex                      208/522 (39.8)      140/289 (48.4)      139/384 (36.2)      137/225 (60.9)      58/180 (32.2)       \<0.001
  Body mass index, kg/m^2^      27.2 (24.1--30.9)   27.9 (24.4--31.3)   27.3 (24.5--30.9)   27.1 (23.7--30.5)   28.0 (25.0--32.0)   0.033
  Logistic EuroScore I, %       12.7 (9.0--19.4)    14.5 (9.5--23.4)    16.3 (10.7--25.3)   24.1 (15.3--35.9)   14.4 (8.1--22.6)    \<0.001
  STS score, %                  5.9 (3.7--9.5)      6.2 (4.0--9.8)      6.7 (4.3--11.2)     7.6 (5.0--12.0)     7.7 (4.2--11.5)     \<0.001
  NYHA class III/IV             358/521 (68.7)      221/289 (76.5)      312/384 (81.2)      199/225 (88.4)      139/180 (77.2)      \<0.001
  CAD                           205/484 (42.4)      149/268 (55.6)      161/359 (44.8)      130/207 (62.8)      76/159 (47.8)       \<0.001
  Previous MI                   44/503 (8.7.)       58/282 (20.6)       46/373 (12.3)       68/221 (30.8)       28/174 (16.1)       \<0.001
  Previous CABG                 33/503 (6.6)        50/282 (17.7)       27/373 (7.2)        49/221 (22.2)       18/174 (10.3)       \<0.001
  Previous PCI                  71/503 (14.1)       73/282 (25.9)       54/373 (14.5)       54/221 (24.4)       33/174 (19.0)       \<0.001
  Arterial hypertension         484/518 (93.4)      270/287 (94.1)      359/381 (94.2)      201/225 (89.3)      172/178 (96.6)      0.044
  Diabetes mellitus             199/521 (38.2)      146/289 (50.5)      158/382 (41.4)      111/225 (49.3)      82/179 (45.8)       0.003
  Atrial fibrillation/flutter   165/522 (31.6)      115/289 (39.8)      177/384 (46.1)      129/225 (57.3)      114/180 (63.3)      \<0.001
  Previous stroke               51/518 (9.8)        29/287 (10.1)       27/381 (7.1)        31/225 (13.8)       23/178 (12.9)       0.068
  PAD                           47/518 (9.1)        35/287 (12.2)       38/381 (10.0)       44/225 (19.6)       19/178 (10.7)       0.001
  COPD                          83/522 (15.9)       53/289 (18.3)       64/384 (16.7)       39/225 (17.3)       27/180 (15.0)       0.872
  CKD stage ≥3b                 140/521 (26.9)      95/289 (32.9)       106/384 (27.6)      83/225 (36.9)       61/180 (33.9)       0.028
  Chronic hemodialysis          9/521 (1.7)         7/288 (2.4)         4/383 (1.0)         11/221 (5.0)        7/177 (4.0)         0.016
  Immunosuppressive therapy     50/522 (9.6)        23/289 (8.0)        30/384 (7.8)        16/224 (7.1)        14/180 (7.8)        0.783
  LV ejection fraction, %       62 (55--69)         57 (48--65)         55 (44--64)         35 (26--45)         62 (57--66)         \<0.001
  Aortic valve area, cm^2^      0.7 (0.6--0.8)      0.8 (0.7--0.9)      0.5 (0.4--0.6)      0.7 (0.5--0.8)      0.7 (0.6--0.8)      \<0.001
  Peak gradient, mm Hg          82 (71--96)         55 (47--61)         78 (71--94)         45 (37--55)         51 (43--60)         \<0.001
  Mean gradient, mm Hg          52 (45--62)         34 (28--38)         51 (45--61)         29 (23--35)         33 (27--37)         \<0.001
  SVI, mL/m^2^                  44 (40--50)         42 (38--48)         29 (24--32)         26 (22--30)         28 (25--32)         \<0.001
  Mitral regurgitation 2/3      32/475 (6.7)        25/269 (9.3)        44/359 (12.3)       53/197 (26.9)       22/168 (13.1)       \<0.001
  Aortic regurgitation 2/3      82/464 (17.7)       28/260 (10.8)       59/353 (16.7)       21/191 (11.0)       15/161 (9.3)        0.009
  NT‐proBNP, pg/mL              1419 (655--3366)    1111 (507--3028)    2854 (1344--5900)   4691 (2415--9230)   1658 (707--3382)    \<0.001

Variables are expressed as number/total (percentage) or median (25th--75th quartile). CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; CKD, chronic kidney disease; cLF‐LG, classic low flow--low gradient; COPD, chronic obstructive lung disease; LF‐HG, low flow--high gradient; LV, left ventricular; MI, myocardial infarction; NF‐HG, normal flow--high gradient; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; pLF‐LG, paradoxical low flow‐low gradient; STS, Society of Thoracic Surgeons; and SVI, stroke volume index.

Procedural Data and Complications {#jah33027-sec-0017}
---------------------------------

Types of implanted valves and Valve Academic Research Consortium‐2--defined device success did not differ between the groups (Table [2](#jah33027-tbl-0002){ref-type="table"}). Analysis of the complication rate at 30 days revealed significant differences between the groups, with higher rates of overall bleeding and access site complications in NF‐HG and pLF‐LG. The other Valve Academic Research Consortium‐2--defined end points, including myocardial infarction, stroke, and kidney injury, did not vary between groups (Table [2](#jah33027-tbl-0002){ref-type="table"}).

###### 

Procedural Outcomes and Mortality at 30 Days and 3‐Year Mortality

  Variables                          NF‐HG (n=543)    NF‐LG (n=306)    LF‐HG (n=392)    cLF‐LG (n=232)   pLF‐LG (n=182)   *P* Value
  ---------------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- -----------
  Type of valve                                                                                                           0.673
  Self‐expandable                    376/521 (72.2)   220/289 (76.1)   290/384 (75.5)   170/225 (75.6)   136/180 (75.6)   
  Balloon expandable                 145/521 (27.8)   69/289 (23.9)    94/384 (24.5)    55/225 (24.4)    44/180 (24.4)    
  Procedure time, min                46 (38--60)      45 (36--56)      48 (39--64)      45 (35--58)      43 (34--57)      0.002
  Contrast dye, mL                   125 (105--154)   120 (100--150)   130 (105--160)   125 (103--150)   120 (100--150)   0.023
  Device success                     455/502 (90.6)   262/282 (92.9)   333/373 (89.3)   205/221 (92.8)   162/174 (93.1)   0.352
  Residual aortic regurgitation ≥2   25/474 (5.3)     10/261 (3.8)     24/341 (7.0)     10/206 (4.9)     7/164 (4.3)      0.459
  Residual mean gradient, mm Hg      9 (7--12)        8 (6--11)        9 (6--11)        7 (5--9)         8 (6--11)        \<0.001
  Aortic valve area, cm^2^           1.9 (1.6--2.2)   1.9 (1.6--2.3)   1.8 (1.5--2.2)   1.9 (1.5--2.2)   1.8 (1.5--2.1)   0.014
  VARC‐2                                                                                                                  
  Myocardial infarction              8/503 (1.6)      0/282 (0.0)      4/373 (1.1)      1/221 (0.5)      1/174 (0.6)      0.194
  Stroke                             19/503 (3.8)     15/282 (5.3)     21/373 (5.6)     14/221 (6.3)     5/174 (2.9)      0.347
  Renal failure                      80/504 (15.9)    47/283 (16.6)    61/376 (16.2)    42/221 (16.2)    35/174 (20.1)    0.650
  Bleeding                           215/503 (42.7)   111/282 (39.4)   152/372 (40.9)   65/221 (29.4)    74/174 (42.5)    0.014
  Access site complication           158/503 (31.4)   68/282 (24.1)    101/373 (27.1)   45/221 (20.4)    56/174 (32.2)    0.011
  New PPM/ICD                        149/521 (28.6)   84/289 (29.1)    120/384 (31.2)   57/225 (25.3)    56/180 (31.1)    0.588
  All‐cause mortality                                                                                                     
  30 d                               35/521 (6.7)     14/287 (4.9)     38/383 (9.9)     20/225 (8.9)     11/180 (6.1)     0.101
  3 y                                129/521 (24.8)   80/287 (27.9)    146/383 (38.1)   79/225 (35.1)    63/180 (35.0)    \<0.001
  Cardiovascular mortality                                                                                                
  30 d                               33/521 (6.4)     13/286 (4.6)     35/383 (9.2)     18/225 (8.1)     8/180 (4.5)      0.093
  3 y                                99/521 (19.0)    58/287 (20.2)    119/383 (31.1)   58/225 (25.8)    46/180 (25.6)    \<0.001

Variables are expressed as number/total (percentage) or median (25th--75th quartile). cLF‐HG indicates classic low flow--high gradient; ICD, implantable cardioverter defibrillator; NF‐HG, normal flow--high gradient; NF‐LG, NF--low gradient; pLF‐LG, paradoxical low flow--low gradient; PPM, permanent pacemaker; and VARC, Valve Academic Research Consortium.

Mortality and Functional Outcome {#jah33027-sec-0018}
--------------------------------

Patients with LF exhibited a significantly higher all‐cause mortality at both 30 days (hazard ratio \[HR\], 1.47; 95% confidence interval \[CI\], 1.02--2.11; *P*=0.041) and 3 years (HR, 1.46; 95% CI, 1.22--1.74; *P*\<0.001) (Figure [1](#jah33027-fig-0001){ref-type="fig"}A), mainly driven by a higher cardiovascular mortality at 3 years (HR, 1.50; 95% CI, 1.22--1.84; *P*\<0.001) (Figure [1](#jah33027-fig-0001){ref-type="fig"}B). Stratifying patients according to MPG (Figure [2](#jah33027-fig-0002){ref-type="fig"}A and [2](#jah33027-fig-0002){ref-type="fig"}B), no significant differences for all‐cause (HR, 1.14; 95% CI, 0.96--1.37; *P*=0.138) and cardiovascular (HR, 1.05; 95% CI, 0.86--1.29; *P*=0.641) mortality were observed in univariate analysis. In contrast, stratifying patients according to LV‐EF, a higher all‐cause (HR, 1.31; 95% CI, 1.09--1.56; *P*=0.004) and cardiovascular (HR, 1.32; 95% CI, 1.08--1.62; *P*=0.008) mortality was observed in patients with LV‐EF ≤50% at 3 years in univariate analysis (Figure [2](#jah33027-fig-0002){ref-type="fig"}C and [2](#jah33027-fig-0002){ref-type="fig"}D).

![All‐cause (A) and cardiovascular (B) mortality according to low flow (LF) vs normal flow (NF). HR indicates hazard ratio.](JAH3-7-e007977-g001){#jah33027-fig-0001}

![All‐cause (A) and cardiovascular (B) mortality according to mean pressure gradient (MPG). All‐cause (C) and cardiovascular (D) mortality according to left ventricular ejection fraction (LV‐EF). HR indicates hazard ratio.](JAH3-7-e007977-g002){#jah33027-fig-0002}

Dividing the population into 5 groups according to SVI, MPG, and LV‐EF, significantly higher all‐cause and cardiovascular mortality rates were observed in patients with cLF‐LG, pLF‐LG, and LF‐HG compared with NF‐HG and NF‐LG (Figure [3](#jah33027-fig-0003){ref-type="fig"}A and [3](#jah33027-fig-0003){ref-type="fig"}B; Table [2](#jah33027-tbl-0002){ref-type="table"}). The all‐cause and cardiovascular mortality rates between cLF‐LG and pLF‐LG were not different at 3 years.

![All‐cause (A) and cardiovascular (B) mortality according to 5 different aortic stenosis entities: normal flow--high gradient (NF‐HG), NF--low gradient (NF‐LG), low flow--HG (LF‐HG), classic LF‐LG (cLF‐LG), and paradoxical LF‐LG (pLF‐LG).](JAH3-7-e007977-g003){#jah33027-fig-0003}

The factors associated with all‐cause and cardiovascular mortality at 3 years are shown in Tables [3](#jah33027-tbl-0003){ref-type="table"} and [4](#jah33027-tbl-0004){ref-type="table"}. Despite including not only preprocedural variables (upper part of Tables [3](#jah33027-tbl-0003){ref-type="table"} and [4](#jah33027-tbl-0004){ref-type="table"}) but also periprocedural complication rates, the presence of LF remained an independent predictor of all‐cause (HR, 1.29; 95% CI, 1.03--1.62; *P*=0.03) and cardiovascular (HR, 1.37; 95% CI, 1.06--1.77; *P*=0.016) mortality. Neither MPG nor LV‐EF at baseline was an independent predictor of mortality in these models (Tables [S1](#jah33027-sup-0001){ref-type="supplementary-material"} through [S4](#jah33027-sup-0001){ref-type="supplementary-material"}).

###### 

Factors Associated With All‐Cause 3‐Year Mortality

  Factors                                                          HR (95% CI)         *P* Value
  ---------------------------------------------------------------- ------------------- -----------
  Parameter (including only preprocedural factors)                                     
  Male sex                                                         1.33 (1.08--1.84)   0.008
  STS score (per 1% increase)                                      1.12 (1.07--1.16)   \<0.001
  NYHA class III/IV                                                1.46 (1.10--1.93)   0.009
  Atrial fibrillation                                              1.28 (1.04--1.57)   0.019
  PAD                                                              1.40 (1.06--1.85)   0.019
  CKD stage ≥3b                                                    1.28 (1.02--1.61)   0.033
  SVI (low flow vs normal flow)                                    1.22 (1.00--1.50)   0.05
  Parameter (including preprocedural and periprocedural factors)                       
  STS score (per 1% increase)                                      1.09 (1.05--1.15)   \<0.001
  NYHA class III/IV                                                1.42 (1.05--1.92)   0.024
  Atrial fibrillation                                              1.36 (1.08--1.71)   0.008
  PAD                                                              1.49 (1.10--2.02)   0.011
  CKD stage ≥3b                                                    1.30 (1.01--1.68)   0.042
  SVI (low flow vs normal flow)                                    1.29 (1.03--1.62)   0.03
  Aortic regurgitation ≥2 (post‐TAVI)                              1.51 (1.03--2.22)   0.036
  VARC‐2 renal failure                                             1.81 (1.38--2.37)   \<0.001

CI indicates confidence interval; CKD, chronic kidney disease; HR, hazard ratio; NYHA, New York Heart Association; PAD, peripheral artery disease; STS, Society of Thoracic Surgeons; SVI, stroke volume index; TAVI, transcatheter aortic valve implantation; and VARC, Valve Academic Research Consortium.

###### 

Factors Associated With Cardiovascular 3‐Year Mortality

  Factors                                                          HR (95% CI)         *P* Value
  ---------------------------------------------------------------- ------------------- -----------
  Parameter (including only preprocedural factors)                                     
  Male sex                                                         1.30 (1.04--1.63)   0.021
  STS score (per 1% increase)                                      1.15 (1.10--1.20)   \<0.001
  NYHA class III/IV                                                1.38 (1.02--1.87)   0.036
  Atrial fibrillation                                              1.39 (1.11--1.74)   0.004
  SVI (low flow vs normal flow)                                    1.28 (1.02--1.59)   0.033
  Parameter (including preprocedural and periprocedural factors)                       
  Male sex                                                         1.32 (1.01--1.71)   0.039
  STS score (per 1% increase)                                      1.15 (1.10--1.21)   \<0.001
  Atrial fibrillation                                              1.56 (1.21--2.02)   0.001
  PAD                                                              1.46 (1.04--2.04)   0.029
  SVI (low flow vs normal flow)                                    1.37 (1.06--1.77)   0.016
  Aortic regurgitation ≥2 (post‐TAVI)                              1.54 (1.02--2.33)   0.042
  VARC‐2                                                                               
  Stroke                                                           1.84 (1.17--2.90)   0.008
  Renal failure                                                    1.83 (1.36--2.47)   \<0.001

CI indicates confidence interval; HR, hazard ratio; NYHA, New York Heart Association; PAD, peripheral artery disease; STS, Society of Thoracic Surgeons; SVI, stroke volume index; TAVI, transcatheter aortic valve implantation; and VARC, Valve Academic Research Consortium.

In terms of functional capacity, significantly more patients with cLF‐LG, pLF‐LG, and LF‐HG were in NYHA class III/IV at baseline in comparison to patients with NF. We found this difference mitigated at 1‐year‐follow‐up, and there was significant symptom improvement in every respective entity between baseline and 1‐year follow‐up (Figure [4](#jah33027-fig-0004){ref-type="fig"}A and [4](#jah33027-fig-0004){ref-type="fig"}B). There were no significant differences between the 5 entities on the proportion of patients with improvement of NYHA class at 1‐year follow‐up (Figure [4](#jah33027-fig-0004){ref-type="fig"}C).

![A, Percentage of patients with respective New York Heart Association (NYHA) functional class for each entity at baseline and at 1 year. B, Percentage of patients with NYHA class III or higher for each entity before and after treatment. C, Percentage of patients in each group with NYHA improvement of ≥1 classes after treatment. cLF‐LG indicates classic low flow--low gradient; LF‐HG, low flow--high gradient; NF‐HG, normal flow--high gradient; and pLF‐LG, paradoxical low flow‐low gradient.](JAH3-7-e007977-g004){#jah33027-fig-0004}

Discussion {#jah33027-sec-0019}
==========

The purpose of this study was to examine the impact of SVI, MPG, and LV‐EF on procedural complications, mortality, and functional capacity after TAVR in a large, single‐center, all‐comers cohort. The main findings of this study include the following: (1) ≈50% of the patients undergoing TAVR are in a state of LF (eg, SVI ≤35 mL/m^2^); (2) LF is associated with higher all‐cause and cardiovascular mortality rates compared with NF; (3) LF, but not LV‐EF or MPG, is an independent predictor of all‐cause and cardiovascular mortality; (4) patients with pLF‐LG had comparable outcomes to patients with cLF‐LG; and (5) despite differences in mortality, surviving patients showed similar improvements in functional capacity across all examined entities of AS.

Incidence and Impact of LF on Outcome {#jah33027-sec-0020}
-------------------------------------

The presence of LF is a common finding in patients with severe AS undergoing surgical aortic valve replacement or TAVR and is reported to range between 30% and 55%.[1](#jah33027-bib-0001){ref-type="ref"}, [19](#jah33027-bib-0019){ref-type="ref"}, [22](#jah33027-bib-0022){ref-type="ref"}, [23](#jah33027-bib-0023){ref-type="ref"} The reasons for LF are multifactorial, including impaired myocardial contractility, restrictive physiological features, and afterload mismatch with high valvuloarterial impedance.[1](#jah33027-bib-0001){ref-type="ref"} Nonrandomized data propose that regardless of the origin, patients with LF have worse outcomes both with and without surgery but may still have an advantage from valve replacement compared with optimal medical therapy.[17](#jah33027-bib-0017){ref-type="ref"}, [30](#jah33027-bib-0030){ref-type="ref"}, [31](#jah33027-bib-0031){ref-type="ref"}

Le et al evaluated the effect of stroke volume on survival after TAVR in 639 patients,[19](#jah33027-bib-0019){ref-type="ref"} Schewel et al in 676 patients,[23](#jah33027-bib-0023){ref-type="ref"} and Reinthaler et al in 150 patients.[22](#jah33027-bib-0022){ref-type="ref"} All these studies revealed a higher mortality in patients with LF. Our study confirms and expands the knowledge about the impact of LF on the outcome of patients undergoing TAVR by corroborating the findings of these smaller studies and proves the independence of SVI as a predictor of mortality. In our study, periprocedural complications were included in the Cox regression models but were not reported[1](#jah33027-bib-0001){ref-type="ref"}, [19](#jah33027-bib-0019){ref-type="ref"} or not included in the multivariable analyses in the aforementioned studies,[23](#jah33027-bib-0023){ref-type="ref"} despite the fact that periprocedural complications are known to affect long‐term mortality.[21](#jah33027-bib-0021){ref-type="ref"} The higher rate of bleeding and access site complications in NF‐HG and pLF‐LG could also be attributed to the higher amount of women in these groups who are known to experience these complications more frequently,[32](#jah33027-bib-0032){ref-type="ref"} but sex was included in our Cox regression model to adjust for this potential confounder. LF is an independent predictor of all‐cause and cardiovascular mortality in both models, including and excluding periprocedural complications underlining the importance and robustness of this factor. Furthermore, procedural complications even affect the outcome up to 3 years.

Impact of LV‐EF and Pressure Gradient on Outcome {#jah33027-sec-0021}
------------------------------------------------

The impact of global LV‐EF, a common parameter incorporated in the classic risk scores,[5](#jah33027-bib-0005){ref-type="ref"} and transvalvular pressure gradient on short‐term and midterm survival after TAVR remain a matter of debate, and numerous large studies found conflicting results. For instance, an analysis of 2535 patients from the UK‐TAVR registry found reduced midterm survival in patients with LG and EF \<50%, whereas patients with normal MPG or preserved EF did not exhibit increased mortality at 2 years.[10](#jah33027-bib-0010){ref-type="ref"} A study with 3908 patients from the German Aortic Valve Registry yielded similar results.[9](#jah33027-bib-0009){ref-type="ref"} A meta‐analysis of 12 589 patients found transvalvular gradient to be an independent predictor of 1‐year mortality but not LV‐EF.[20](#jah33027-bib-0020){ref-type="ref"} In our study, reduced LV‐EF was associated with a higher mortality in univariate analysis; however, after adjusting for other risk factors, including SVI, this association lost significance. Transvalvular pressure gradient was not associated with 30‐day or 3‐year mortality in our analysis. The reason for those divergent findings might be caused by heterogeneous group definitions (eg, LV‐EF \<30% versus \>30% or \<50% versus \>50%), bias inherent to observational studies, and, most important, missing measurement/incorporation of SVI. LV‐EF does not adequately reflect total LV function in a setting of marked LV hypertrophy and relatively small LV volumes typical of high‐grade AS.[18](#jah33027-bib-0018){ref-type="ref"} Reduced MPG can be interpreted as an effect of low transvalvular flow secondary to LV dysfunction or concomitant mitral regurgitation, but without knowledge of SVI, this entity cannot be discerned from LG because of only moderately reduced aortic valve area. Therefore, the inverse relationship between baseline gradient and mortality after TAVR is possibly explained by the occurrence of LF, which has not been determined in those studies.[20](#jah33027-bib-0020){ref-type="ref"} All these findings suggest that SVI, as a direct measure of cardiac systolic function, is a more important determinant of outcome than the mechanism leading to the LF state.

"pLF‐LG" and "cLF‐LG" AS {#jah33027-sec-0022}
------------------------

The impact of pLF‐LG on outcome compared with cLF‐LG and NF‐HG has been conversely debated. Studies show comparable outcomes to NF‐HG,[9](#jah33027-bib-0009){ref-type="ref"} a higher mortality in pLF‐LG compared with NF‐HG but lower compared with cLF‐LG,[23](#jah33027-bib-0023){ref-type="ref"} and those with equal mortality rates in pLF‐LG and cLF‐LG but higher compared with NF‐HG.[19](#jah33027-bib-0019){ref-type="ref"} Our findings confirm the high prevalence of pLF‐LG and similar worse prognosis of those patients compared with cLF‐LG, which is in line with those studies integrating SVI as an essential parameter for group definition.[1](#jah33027-bib-0001){ref-type="ref"}, [19](#jah33027-bib-0019){ref-type="ref"}, [22](#jah33027-bib-0022){ref-type="ref"}, [23](#jah33027-bib-0023){ref-type="ref"} These data support the above mentioned thesis that flow, rather than the mechanism for reduced flow, is the key prognostic factor[1](#jah33027-bib-0001){ref-type="ref"} and that an LF state might be a sign for an advanced disease. The divergence compared with the analysis derived from the German Aortic Valve Registry[9](#jah33027-bib-0009){ref-type="ref"} might be caused by the definition of pLF‐LG, including only LV‐EF ≥50% and MPG \<40 mm Hg but not SVI, which may have led to the inclusion of nonsevere AS in this group. Despite the higher mortality in pLF‐LG and cLF‐LG after TAVR, those patients derive a mortality benefit from valve replacement compared with medical therapy, which seems to be comparable between TAVR and surgical aortic valve replacement.[1](#jah33027-bib-0001){ref-type="ref"}, [17](#jah33027-bib-0017){ref-type="ref"}

Beyond mortality, surviving patients in all LF groups had a significant improvement in functional symptoms, which was comparable to NF‐HG and NF‐LG in our analysis and another study,[23](#jah33027-bib-0023){ref-type="ref"} indicating that treatment needs to be considered in patients with LF, despite a higher mortality compared with patients with NF.

Limitations {#jah33027-sec-0023}
-----------

Our study has several limitations that should be noted. Data collected were derived from a single‐center registry and are, therefore, prone to bias inherent to registries and not necessarily conferrable to other cohorts. There was no core laboratory to analyze echocardiography. Echocardiographic estimation of SVI is susceptible to measurement errors, in particular in elliptic shape of the LV outflow tract, atrial fibrillation, concomitant aortic and mitral regurgitation, or poor image quality.[28](#jah33027-bib-0028){ref-type="ref"} Dobutamine stress echocardiography was not performed on a regular basis. Thus, we were not able to estimate contractile reserve, which is known to affect the outcome of patients with cLF‐LG.[31](#jah33027-bib-0031){ref-type="ref"} Only little is known about the role of dobutamine stress echocardiography in pLF‐LG.[33](#jah33027-bib-0033){ref-type="ref"} The assessment of calcium score has gained increasing importance in the diagnosis of LF‐LG because the degree of valve calcification by computed tomography is related to AS severity and outcome. Unfortunately, calcium score was not available in our registry to further differentiate this entity. However, comparable NT‐proBNP values in NF‐HG, NF‐LG, and pLF‐LG and the even higher values in LF‐HG and cLF‐LG are reassuring that all patients experienced a real severe AS. Finally, NYHA class is a subjective parameter for assessing functional outcome, but more sophisticated examinations (eg, 6‐minute walk test and quality‐of‐life questionnaires) were not performed in our registry.

Conclusion {#jah33027-sec-0024}
==========

LF, defined by SVI ≤35 mL/m^2^, is a common finding within the AS population. LF, but not LV‐EF or MPG, is an independent predictor of all‐cause and cardiovascular mortality. The results of this study underline the importance to determine SVI during evaluation of patients with severe AS for diagnosis and risk assessment, as recommended in current guidelines. Despite a significantly higher long‐term mortality in patients with pLF‐LG and cLF‐LG, the high procedural success rates, heightened, yet low, procedural mortality, and the excellent improvement in functional capacity of the surviving patients suggest that these are rather patients in need for an early treatment because of advanced disease than a futile patient cohort. Randomized controlled trials would need to test this hypothesis.
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